Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
Public ClinicalTrials.gov record NCT02614898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evidence - Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Study identification
- NCT ID
- NCT02614898
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Interventions
- Eculizumab Other
Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2015
- Primary completion
- Oct 4, 2017
- Completion
- Oct 4, 2017
- Last update posted
- Jan 1, 2020
2015 – 2017
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Washington D.C. | District of Columbia | 20007 | — |
| Clinical Trial Site | Atlanta | Georgia | 30322 | — |
| Clinical Trial Site | Chicago | Illinois | 60611 | — |
| Clinical Trial Site | Boston | Massachusetts | 02115 | — |
| Clinical Trial Site | Hackensack | New Jersey | 07601 | — |
| Clinical Trial Site | Charlotte | North Carolina | 28203 | — |
| Clinical Trial Site | Columbus | Ohio | 43210 | — |
| Clinical Trial Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02614898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 1, 2020 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02614898 live on ClinicalTrials.gov.